COMMUNIQUÉS West-GlobeNewswire

Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
13/07/2026
Cumulative sales milestones up to $255 million and modest upfront/near-term development milestones Royalties equaling 22% of net sales Ocugen to manufacture and supply OCU400 MALVERN, Pa., July 13, 2026 (GLOBE NEWSWIRE [...]
Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit
13/07/2026
PURCHASE, N.Y., July 13, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and [...]
First patient treated in Phase 2 A-TANGO trial for acute-on-chronic liver failure
13/07/2026
Randomized phase 2 study evaluating Yaqrit’s toll-like receptor 4 (TLR4) antagonist YAQ005 alone and in combination with G-CSF for acute-on-chronic liver failure (ACLF) Investigational combination G-TAK is designed to [...]
FDA Grants De Novo Classification to Claria Medical for Device Designed to Improve Safety and Efficiency of Hysterectomy Procedures
13/07/2026
Claria System is the first integrated tissue containment and removal system authorized by the FDA, granted through its Safer Technologies Program for its potential impact on women’s health MOUNTAIN VIEW, Calif., July 13 [...]
Geron Announces Appointment of Chinmaya Rath as Chief Business Officer
13/07/2026
Mr. Rath brings senior leadership experience in business development across a range of biopharmaceutical companies FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial- [...]
Bexorg Expands Leadership Team with Appointments of Bruce Car, Ph.D., as Chief Scientific Officer and Michael Fenn, Ph.D., as Chief Business Officer
13/07/2026
- Dr. Car brings more than 30 years of drug discovery experience to lead Bexorg's next phase of clinical translation; Dr. Fenn joins Bexorg to lead business development, asset strategy, and corporate development - [...]
Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
13/07/2026
Topline data expected to be available late 3Q2027 SOUTH SAN FRANCISCO, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on [...]
Apollomics Regains Full Compliance with Nasdaq Listing Requirements
13/07/2026
FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to [...]
Bavarian Nordic’s Chikungunya Vaccine Submitted for Regulatory Approval in Brazil
13/07/2026
COPENHAGEN, Denmark, July 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that its partner, Eurofarma, has submitted a marketing authorization application to the Brazilian Health Regulatory Agency (Anvisa) [...]
Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026
13/07/2026
- Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to [...]
Fortrea Announces Date for Second Quarter 2026 Financial Results and Conference Call
13/07/2026
DURHAM, N.C., July 13, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its second quarter 2026 financial [...]
Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease
13/07/2026
Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC) entitled “ Laromestrocel Stabilizes Brain Inflammation In Key Alzheimer’s Disease Gray And White Matter Regions As Assessed Using [...]
NetraMark Engages AM Public Relations to Support Strategic Communications and Market Awareness
13/07/2026
Collaboration intended to support broader awareness of NetraMark's clinical development initiatives and NetraAI platform TORONTO, July 13, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc . (the "Company" or "NetraMark [...]
REPEAT - Grifols deaths and harm: Patient safety & options for accountability
13/07/2026
TORONTO, July 13, 2026 (GLOBE NEWSWIRE) -- Will Trial Lawyers and the Ontario Health Coalition invite members of the media to attend a press conference regarding patient safety issues related to Grifols, one of the [...]
Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis
13/07/2026
FDA grant of RMAT designation to Allocetra™ reinforces the potential of this program to deliver a meaningful, disease-modifying impact in age-related primary knee osteoarthritis, where patients face declined quality-of- [...]
Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®
13/07/2026
New agreement, effective January 1, 2027, to add approximately 9 million Medicare lives (16% of approximately 55 million Medicare lives in the U.S.) On top of two previously announced major commercial payer agreements [...]
Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress
13/07/2026
Selected as one of three late-breakthrough abstracts: clinical trials and innovation in thrombosis, CAD-1005 took center stage before the global thrombosis community at the largest ISTH meeting in more than a decade. [...]
Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio
13/07/2026
Received two new U.S. Rezdiffra ® (resmetirom) patents in F2/F3; both patents will be listed in the FDA’s Orange Book Received new U.S. resmetirom patent directed to a method of administering resmetirom to treat well- [...]
ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis
13/07/2026
Trial met both co-primary endpoints of mean change from baseline in BCVA letter score and mean change from baseline CST with statistical significance at 6 months The most common adverse events reported were consistent [...]

Pages